Compare GSK plc (GSK) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lockheed Martin Corporation — how do they compare? GSK plc trades at $52.68 (market cap $101.34B), while Lockheed Martin Corporation trades at $514.78 (market cap $118.62B). The key difference: Lockheed Martin Corporation is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LMT | |
|---|---|---|
Market Cap | $101.34B | $118.62B |
Sector | Health | Industrials |
52-Week High | $61.18 | $676.70 |
52-Week Low | $36.20 | $410.74 |
Enterprise Value | $121.95B | $137.42B |
Dividend Yield | 3.49% | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Lockheed Martin (LMT) trades at $515.75, up 0.15% on the day, with a bearish technical signal but strong analyst support. The stock shows robust fundamentals including a $75.05B revenue in 2025, a 6.38% net income margin, and a high ROE of 67.64%. Recent news highlights expansion into European venture capital and a $194B backlog, signaling long-term demand. However, earnings misses in Q4 2025 and Q1 2026 pose near-term execution challenges amid escalating defense spending trends.
The outlook for LMT is positive due to strong defense budgets and a massive backlog, but risks include earnings volatility and high debt levels. With 57% of analysts rating it Buy and a consensus price target of $614, the stock offers potential upside, though investors should monitor margin improvements and geopolitical developments affecting defense contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
